NR1I2

Across TCGA pan-cancer cohorts, NR1I2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of NR1I2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NR1I2 RNA is repressed in tumor relative to normal tissue. In most cancer types NR1I2 is over-expressed in tumor, although a few such as LIHC and KICH show the opposite, repressed pattern.

LIHC, KICH, and KIRC are the cancer types where NR1I2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NR1I2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	−1.713	<.001	8	view →
KICH	All	All	−0.193	<.001	8	view →
KIRC	All	All	+0.092	<.001	7	view →
THCA	Female	All	+0.124	.001	6	view →
CHOL	Female	All	−4.733	<.001	5	view →
BRCA	All	IV	−0.245	.043	4	view →
ESCA	All	II,III,IV	+2.215	.045	2	view →
STAD	All	II,III,IV	+1.130	.041	2	view →
KIRP	Male	All	+0.120	.025	2	view →
PRAD	All	All	−0.058	<.001	2	view →
COAD	Female	II,III,IV	−0.565	.031	1	view →
LUAD	All	All	+0.180	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

NR1I2–LIHC

Open the LIHC breakdown →